Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 8/20 | 0.36 |
| ▸ | DRD4 | P21917 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6461768 | 0.82 | HTR1A (0.41) | HTR1ADRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL6466061 | 0.75 | DRD2 (0.38) | HTR1ADRD2DRD3ALDH1A1 | |
| SCHEMBL1444940 | 0.72 | HTR6 (0.49) | HTR1ADRD2DRD3ALDH1A1TSHR | |
| SCHEMBL6461339 | 0.71 | ATM (0.32) | HTR1ADRD2DRD4DRD3HTR6 | |
| SCHEMBL9403868 | 0.71 | L3MBTL1 (0.58) | ALDH1A1TSHRHTR7 | |
| SCHEMBL6460817 | 0.71 | DRD2 (0.41) | HTR1ADRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL5675675 | 0.70 | DRD2 (0.41) | HTR1ADRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL6463756 | 0.70 | DRD2 (0.42) | HTR1ADRD2DRD4DRD3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2988937 | 0.69 | DRD2 (0.58) | HTR1ADRD2DRD4DRD3HTR7 | |
| SCHEMBL6462545 | 0.69 | DRD2 (0.39) | HTR1ADRD2DRD4DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881841-B2 | Dibenzosuberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives | Takeuchi, Tsutomu (JP) | 2005-04-19 | — | — | US | claimed |
| US-20040029895-A1 | Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives | TAKAYANAGI, HIROAKI (JP) | 2004-02-12 | — | — | US | claimed |
| EP-1336608-A1 | DIBENZOSBERANYL PIPERAZINE DERIVATIVES AND DRUG-RESISTANCE OVERCOMING AGENTS CONTAINING THE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-08-20 | — | — | EP | claimed |
| US-6881841-B2 | Dibenzosuberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives | Takeuchi, Tsutomu (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20040029895-A1 | Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives | TAKAYANAGI, HIROAKI (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1336608-A1 | DIBENZOSBERANYL PIPERAZINE DERIVATIVES AND DRUG-RESISTANCE OVERCOMING AGENTS CONTAINING THE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029895-A1 | Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives | ABCC1, ABCB1, SLC11A2 | HTR1A 3114/4885DRD2 1484/4885DRD4 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.